SWISS CLINICAL TRIAL ORGANISATION (SCTO)

Their core work

SCTO is Switzerland's national coordinating body for clinical research infrastructure, working to improve the quality, efficiency, and regulatory framework of clinical trials across the country. They bring deep expertise in paediatric clinical trials, connecting national trial networks with European research infrastructures. Their practical contribution lies in standardizing trial processes, providing expert advice on clinical development, and ensuring that clinical research — particularly for children and adolescents — meets best-practice standards across borders.

What they specialise in

How they've shifted over time

SCTO's early H2020 work (2017-2018) was tightly focused on building European paediatric research infrastructure — creating networks and frameworks for drug development in children. From 2019 onward, their scope broadened significantly: the c4c project deepened their paediatric work into clinical development best practices and education, while EU-RESPONSE pivoted them into pandemic preparedness and platform trials for infectious diseases. This shift from infrastructure-building to operational trial networks — and from paediatrics-only to broader public health emergencies — shows a maturing organization expanding its remit.

SCTO is moving from building paediatric trial infrastructure toward operating multi-disease platform trial networks, positioning them for pandemic preparedness and adaptive clinical trial design collaborations.

How they like to work

SCTO consistently joins as a participant in large European consortia — they have never coordinated an H2020 project, instead contributing specialist expertise to networks led by others. With 163 unique partners across 30 countries, they are highly connected, particularly through mega-projects like c4c (their largest by funding). This makes them a well-networked, reliable partner who brings national-level clinical trial coordination experience into large multinational frameworks.

SCTO has collaborated with 163 unique partners across 30 countries, giving them a genuinely pan-European network. Their connections span university hospitals, regulatory agencies, and research infrastructures — particularly strong in Western Europe through paediatric and clinical trial consortia.

What sets them apart

SCTO occupies a rare niche as a national clinical trial organisation that bridges Swiss clinical research infrastructure with EU-wide networks — important given Switzerland's complex relationship with EU research programmes. Their deep specialisation in paediatric trials makes them one of few organisations that can coordinate child-specific clinical research across regulatory boundaries. For consortium builders, they offer a Swiss entry point with established connections to 30 countries and credibility in both trial methodology and regulatory compliance.

Highlights from their portfolio

• c4c
  Their largest project (EUR 907K funding), a major European network for paediatric clinical trials covering drug development, education, and best practices across the full age range from neonates to adolescents.
• EU-RESPONSE
  Marks a strategic pivot into pandemic preparedness and platform trials for emerging infectious diseases, with EUR 384K in funding running through 2026.
• EOSC-Life
  Connects SCTO to the European Open Science Cloud ecosystem as a third party, linking clinical trial data management to broader FAIR and open-science infrastructure.